Key Points
- EVP Michael Feld sold 75 shares on Jan. 26 at an average of $202.73 (≈$15.2k), trimming his stake by about 0.45% — a very small insider sale unlikely to materially affect investor sentiment.
- The board set record (Feb. 5) and distribution/closing (Feb. 9) dates for the spin-off of BD’s Biosciences & Diagnostic Solutions unit, and Waters shareholders approved the combination — a structural move that could unlock shareholder value.
- The board declared a $1.05 quarterly dividend (payable Mar. 31; yield ~2.1%) and authorized an additional $10M in share repurchases after completing roughly $250M YTD, signaling cash returns and management confidence (the $10M authorization is small relative to BD’s market cap).
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 75 shares of the firm's stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $202.73, for a total transaction of $15,204.75. Following the sale, the executive vice president directly owned 16,431 shares of the company's stock, valued at $3,331,056.63. The trade was a 0.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Michael Feld also recently made the following trade(s):
- On Friday, December 26th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $196.08, for a total transaction of $14,509.92.
- On Monday, December 1st, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $193.36, for a total transaction of $14,502.00.
Becton, Dickinson and Company Stock Performance
Shares of BDX stock opened at $201.81 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99. The company's 50-day simple moving average is $198.08 and its 200-day simple moving average is $190.98. The stock has a market capitalization of $57.50 billion, a price-to-earnings ratio of 34.62, a PEG ratio of 2.25 and a beta of 0.23.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The firm had revenue of $5.89 billion during the quarter, compared to analyst estimates of $5.91 billion. During the same period in the previous year, the company earned $3.81 earnings per share. Becton, Dickinson and Company's quarterly revenue was up 8.3% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 72.04%.
Becton, Dickinson and Company declared that its board has approved a share repurchase program on Tuesday, January 27th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on the stock. Royal Bank Of Canada raised their price target on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a "sector perform" rating in a research report on Wednesday, December 17th. Weiss Ratings reissued a "hold (c-)" rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Morgan Stanley upped their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an "overweight" rating in a report on Tuesday, December 2nd. Jefferies Financial Group raised their price target on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a "buy" rating in a report on Wednesday, December 10th. Finally, Bank of America upped their price objective on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a "neutral" rating in a research note on Monday, January 5th. Four investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $209.00.
Check Out Our Latest Report on Becton, Dickinson and Company
Institutional Trading of Becton, Dickinson and Company
Several large investors have recently added to or reduced their stakes in the business. Crux Wealth Advisors boosted its position in Becton, Dickinson and Company by 0.8% during the 4th quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier's stock worth $1,222,000 after acquiring an additional 49 shares during the period. Bill Few Associates Inc. lifted its holdings in Becton, Dickinson and Company by 0.7% in the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier's stock worth $1,362,000 after purchasing an additional 55 shares during the period. McElhenny Sheffield Capital Management LLC grew its position in Becton, Dickinson and Company by 3.6% in the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier's stock valued at $309,000 after buying an additional 55 shares in the last quarter. Gilbert & Cook Inc. increased its stake in Becton, Dickinson and Company by 2.0% during the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier's stock valued at $490,000 after buying an additional 56 shares during the period. Finally, Mendel Money Management raised its position in shares of Becton, Dickinson and Company by 2.6% during the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier's stock worth $388,000 after buying an additional 58 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Key Becton, Dickinson and Company News
Here are the key news stories impacting Becton, Dickinson and Company this week:
- Positive Sentiment: Board set the record date (Feb 5) and distribution/closing date (Feb 9) for the spin-off of BD’s Biosciences & Diagnostic Solutions business — a structural move that could unlock value for shareholders. BD Announces Record Date for the Spin-Off
- Positive Sentiment: Waters Corporation shareholders approved the combination with BD’s Biosciences & Diagnostic Solutions unit, clearing a key step toward the planned transaction that underpins the spin-off strategy. Waters Shareholders Approve Combination
- Positive Sentiment: Board declared a $1.05 quarterly dividend (payable Mar 31; record/ex-div Mar 10), supporting income-focused investors and signaling cash-return discipline. BD Board Declares Dividend, Authorizes Repurchases
- Positive Sentiment: Company authorized an additional $10 million in share repurchases and has completed ~$250 million of repurchases year-to-date, which can support EPS and signal management confidence (note: $10M is small vs. market cap). Board Authorizes Additional Repurchases
- Positive Sentiment: Launched BD Research Cloud 7.0 with AI-powered features for flow cytometry — product innovation that can drive competitive positioning in diagnostics and recurring software/service revenue over time. BDX Introduces BD Research Cloud 7.0
- Neutral Sentiment: BD will release quarterly earnings and host a management webcast — an upcoming catalyst that could cause short-term volatility depending on results vs. guidance. BD to Release Quarterly Earnings
- Neutral Sentiment: Analyst and media pieces highlight BDX as a long-term value name versus peers; useful for investor sentiment but not an immediate price mover. Why Becton Dickinson is a Top Value Stock
- Negative Sentiment: Insider activity: EVP Michael Feld sold 75 shares (~$15.2k) on Jan 26 — a very small reduction in holdings (0.45% of his stake) that is unlikely to materially affect investor view but may be cited by short-term traders. SEC Form 4 - Michael Feld Sale
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
